# LENZ Therapeutics, Inc. (LENZ)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $187M  
**Price:** $6.50 (-1.22%)

> LENZ Therapeutics, Inc. is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. This innovative once-daily eye drop aims to restore near vision, addressing the gradual loss of focusing ability that affects adults typically over age 45, offering a pharmaceutical alternative to reading glasses for a broad patient population. The company is actively commercializing VIZZ™ in the United States while establishing licensing partnerships internationally to expand global access. Headquartered in Solana Beach, California, LENZ Therapeutics operates in the ophthalmic pharmaceuticals sector, supported by a leadership team with deep expertise in biopharmaceutical development, clinical operations, regulatory affairs, manufacturing, marketing, sales, and commercial strategy. Their novel product targets the presbyopia market, providing a targeted solution to improve vision clarity and quality of life for millions impacted by this common age-related condition.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $19M | $19M | -$91M | -$82M | $-2.85 |
| 2024 | — | — | -$59M | -$50M | $-2.34 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $306M | $22M | $284M | $25M | — |
| 2024 | $215M | $11M | $204M | $20M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$69M | $827,000 | -$70M |
| 2024 | -$59M | $468,000 | -$60M |
| 2023 | -$60M | $30,000 | -$60M |
| 2022 | -$88M | $7M | -$95M |
| 2021 | -$53M | $6M | -$59M |
| 2020 | -$9M | $2M | -$10M |

Source: [CompaniesByCap](https://companiesbycap.com/company/LENZ)